Larimar Therapeutics

Larimar Therapeutics (LRMR) will host a conference call and webcast on September 29, 2025, at 8:00 am EDT to provide updates on its nomlabofusp clinical development program. The presentation will feature data from the ongoing long-term open-label study evaluating nomlabofusp for the treatment of Friedreich’s ataxia (FA). The company aims to demonstrate the drug’s long-term efficacy and safety in FA patients, addressing a significant unmet medical need. A webcast replay will be available on Larimar’s website.